Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine
Authors
Keywords
Vaccines, Vaccination and immunization, Cost-effectiveness analysis, Immunity, Age groups, Human papillomavirus infection, Human papillomavirus, Cervical cancer
Journal
PLoS One
Volume 8, Issue 9, Pages e75552
Publisher
Public Library of Science (PLoS)
Online
2013-09-27
DOI
10.1371/journal.pone.0075552
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
- (2013) Jane J. Kim ANNALS OF INTERNAL MEDICINE
- Male vaccination against human papillomavirus
- (2012) David M Salisbury LANCET INFECTIOUS DISEASES
- End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
- (2011) X Castellsagué et al. BRITISH JOURNAL OF CANCER
- Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
- (2011) A. Szarewski et al. INTERNATIONAL JOURNAL OF CANCER
- Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses
- (2011) Tjalke A. Westra et al. JOURNAL OF INFECTIOUS DISEASES
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
- (2011) Aimée R. Kreimer et al. JNCI-Journal of the National Cancer Institute
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands
- (2011) Johannes A. Bogaards et al. VACCINE
- The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey
- (2009) D. Lévy-Bruhl et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom
- (2009) Yoon Hong Choi et al. VACCINE
- Determinants for HPV vaccine uptake in the Netherlands: A multilevel study
- (2009) Marc Rondy et al. VACCINE
- Age-Based Programs for Vaccination against HPV
- (2009) Elamin H. Elbasha et al. VALUE IN HEALTH
- Health and Economic Implications of HPV Vaccination in the United States
- (2008) Jane J. Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started